Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease

Vitamin D secosteroids are intranuclear regulators of cellular growth and suppress the renin-angiotensin system. The aim of this study was to test the hypothesis that the vitamin D receptor agonist, paricalcitol (PC), either alone or with enalapril (E) (an angiotensin-converting enzyme inhibitor), r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Priyanka S. Sagar, Sayanthooran Saravanabavan, Alexandra Munt, Annette T. Y. Wong, Gopala K. Rangan
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	polycystic kidney disease paricalcitol vitamin D receptor agonists Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/90f1a31418fb4508a9399ef95e7e89f3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90f1a31418fb4508a9399ef95e7e89f3
record_format	dspace
spelling	oai:doaj.org-article:90f1a31418fb4508a9399ef95e7e89f32021-11-25T18:00:17ZEffect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease10.3390/jcdd81101442308-3425https://doaj.org/article/90f1a31418fb4508a9399ef95e7e89f32021-10-01T00:00:00Zhttps://www.mdpi.com/2308-3425/8/11/144https://doaj.org/toc/2308-3425Vitamin D secosteroids are intranuclear regulators of cellular growth and suppress the renin-angiotensin system. The aim of this study was to test the hypothesis that the vitamin D receptor agonist, paricalcitol (PC), either alone or with enalapril (E) (an angiotensin-converting enzyme inhibitor), reduces the progression of polycystic kidney disease. Preventative treatment of Lewis polycystic kidney (LPK) and Lewis control rats with PC (0.2 μg/kg i.p. 5 days/week) or vehicle from postnatal weeks 3 to 10 did not alter kidney enlargement. To evaluate the efficacy in established disease, LPK rats received either PC (0.8 μg/kg i.p; 3 days/week), vehicle, E (50 mg/L in water) or the combination of PC + E from weeks 10 to 20. In established disease, PC also did not alter the progression of kidney enlargement, kidney cyst growth or decline in renal function in LPK rats. Moreover, the higher dose of PC was associated with increased serum calcium and weight loss. However, in established disease, the combination of PC + E reduced systolic blood pressure and heart-body weight ratio compared to vehicle and E alone (<i>p</i> < 0.05). In conclusion, the combination of PC + E attenuated cardiovascular disease but caused hypercalcaemia and did not alter kidney cyst growth in LPK rats.Priyanka S. SagarSayanthooran SaravanabavanAlexandra MuntAnnette T. Y. WongGopala K. RanganMDPI AGarticlepolycystic kidney diseaseparicalcitolvitamin D receptor agonistsDiseases of the circulatory (Cardiovascular) systemRC666-701ENJournal of Cardiovascular Development and Disease, Vol 8, Iss 144, p 144 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	polycystic kidney disease paricalcitol vitamin D receptor agonists Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	polycystic kidney disease paricalcitol vitamin D receptor agonists Diseases of the circulatory (Cardiovascular) system RC666-701 Priyanka S. Sagar Sayanthooran Saravanabavan Alexandra Munt Annette T. Y. Wong Gopala K. Rangan Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
description	Vitamin D secosteroids are intranuclear regulators of cellular growth and suppress the renin-angiotensin system. The aim of this study was to test the hypothesis that the vitamin D receptor agonist, paricalcitol (PC), either alone or with enalapril (E) (an angiotensin-converting enzyme inhibitor), reduces the progression of polycystic kidney disease. Preventative treatment of Lewis polycystic kidney (LPK) and Lewis control rats with PC (0.2 μg/kg i.p. 5 days/week) or vehicle from postnatal weeks 3 to 10 did not alter kidney enlargement. To evaluate the efficacy in established disease, LPK rats received either PC (0.8 μg/kg i.p; 3 days/week), vehicle, E (50 mg/L in water) or the combination of PC + E from weeks 10 to 20. In established disease, PC also did not alter the progression of kidney enlargement, kidney cyst growth or decline in renal function in LPK rats. Moreover, the higher dose of PC was associated with increased serum calcium and weight loss. However, in established disease, the combination of PC + E reduced systolic blood pressure and heart-body weight ratio compared to vehicle and E alone (<i>p</i> < 0.05). In conclusion, the combination of PC + E attenuated cardiovascular disease but caused hypercalcaemia and did not alter kidney cyst growth in LPK rats.
format	article
author	Priyanka S. Sagar Sayanthooran Saravanabavan Alexandra Munt Annette T. Y. Wong Gopala K. Rangan
author_facet	Priyanka S. Sagar Sayanthooran Saravanabavan Alexandra Munt Annette T. Y. Wong Gopala K. Rangan
author_sort	Priyanka S. Sagar
title	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
title_short	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
title_full	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
title_fullStr	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
title_full_unstemmed	Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
title_sort	effect of early and delayed commencement of paricalcitol in combination with enalapril on the progression of experimental polycystic kidney disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/90f1a31418fb4508a9399ef95e7e89f3
work_keys_str_mv	AT priyankassagar effectofearlyanddelayedcommencementofparicalcitolincombinationwithenalaprilontheprogressionofexperimentalpolycystickidneydisease AT sayanthooransaravanabavan effectofearlyanddelayedcommencementofparicalcitolincombinationwithenalaprilontheprogressionofexperimentalpolycystickidneydisease AT alexandramunt effectofearlyanddelayedcommencementofparicalcitolincombinationwithenalaprilontheprogressionofexperimentalpolycystickidneydisease AT annettetywong effectofearlyanddelayedcommencementofparicalcitolincombinationwithenalaprilontheprogressionofexperimentalpolycystickidneydisease AT gopalakrangan effectofearlyanddelayedcommencementofparicalcitolincombinationwithenalaprilontheprogressionofexperimentalpolycystickidneydisease
_version_	1718411758755905536

Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease

Ejemplares similares